TTP is seen in acquired immunodeficiency syndrome patients with a low helper T cells (CD4+) count (<200 cells/μL) and high viral loads, and the incidence of HIV‐associated TTP was expected to decline with widespread access to anti‐retroviral therapy (ART). This evidence concerns the gene CD4 and thrombotic thrombocytopenic purpura.